Cell and Gene Therapy for Personalised Medicine (CGT4PM2027)
Preliminary Announcement for the Joint Transnational Call (JTC) 2027
The European Partnership for Personalised Medicine, EP PerMed (supported by the European Union under Horizon Europe, Grant Agreement N° 101137129), is a platform for joint programming of national and European regional research and innovation supporting activities putting into action “The Strategic Research & Innovation Agenda (SRIA) for Personalised Medicine (2023)”, SRIA for PM (2023), through dedicated research, development and innovation funding.
The EP PerMed funding organisations listed below have agreed to launch the joint transnational call 2027 (JTC2027) “Cell and Gene Therapy for Personalised Medicine” (acronym: CGT4PM2027), co-funded by the European Union, to fund multinational, innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe and beyond in this field. The JTC2027 will be conducted simultaneously by the participating funding organisations in their respective region/country and coordinated centrally by the Joint Call Secretariat (JCS), hosted by the French National Research Agency (ANR), France.
The call will be implemented in two stages, i.e. a pre- and a full proposal phase. The available budget for this call is 33 Mio. € (approx.).
Expected timeline of the call
| Date | Event |
|---|---|
| 04 November 2026 | Publication of the call |
| 03 December 2026 | Information day |
| 20 January 2027 (14:00, CET) | Deadline for pre-proposal submission |
| Beginning of April 2027 | Communication of the results of the pre-proposal assessment and invitation to the full proposal stage |
| 25 May 2027 (14:00, CEST) | Deadline for full proposal submission |
| Beginning of August 2027 | Rebuttal stage |
| Expected for October 2027 | Communication of the funding decisions to the applicants |
| End of 2027 / beginning of 2028 | Expected project start (according to regional/national funding regulations) |
Change Log
13 October 2026
Publication of the pre-announcement
Aims of the Call
With this JTC, EP PerMed will fund research projects in human health on Cell and Gene Therapy (CGT) for PM approaches. Proposals must focus on the development and validation of an innovative and novel CGT for PM.
At least one of the following approaches must be employed:
- Somatic cell therapeutics;
- Gene therapeutics;
- Combined cell- and gene therapeutics;
- Novel biological products such as mRNA, other nucleic acid-based methods, and extracellular vesicles as vehicle for gene-based therapeutic procedure.
Research projects in all disease areas are encouraged.
EP PerMed overall aims to:
- Encourage and enable interdisciplinary collaborations, i.e. multi-actor research, by engaging a range of relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to facilitate the implementation of PM;
- Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises, industry), as well as regulatory/HTA (health technology assessment) agencies and patient organisations.
General (Eligibility) Conditions for Application
Joint research proposals may be submitted by applicants belonging to the following categories (subject to regional/national funding regulations):
- Academia (research teams working in universities, other higher education institutions) or research institutes;
- Clinical/public health sector (research teams working in hospitals/public health and/or other healthcare settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses) in the research teams is encouraged;
- Private for-profit (industry) partners, e.g. SME (small and medium-sized enterprises)and private non-profit partners, e.g. foundations, associations or non-governmental organisations.
Whilst applications will be submitted jointly by groups from several countries, the individual applicants of each group will be funded by the respective regional/national EP PerMed funding organisation of the individual applicants. The applications are therefore subject to eligibility criteria and regulations of individual funding organisations. Applicants are strongly advised to contact their regional/ national representatives of the participating relevant funding organisation as soon as possible in order to confirm their eligibility (see also below “Contact details of participating members”).
More information about the eligibility criteria and rules regarding consortium composition will be available soon.
Partnering Tool
A partnering tool developed and supported by EP PerMed is available for the call.
Participating Countries and European Regions
The following countries (25) are participating in the preparation of the call: Austria, Belgium*, Canada, Czech Republic, Estonia, Finland, France*, Germany, Greece*, Hungary, Ireland, Israel, Italy*, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal*, Romania, Slovak Republic, Spain, Sweden, The Netherlands and Turkiye* (contact list is provided below).
Five of the participating countries are represented by their specific regions (10): Flanders (Belgium)*, Wallonia-Brussels Federation (Belgium), Wallonia (Belgium), Saxony (Germany), Friuli-Venezia Giulia (Italy), Lombardy (Italy)*, Tuscany (Italy), Azores (Portugal), Andalusia (Spain), and Catalonia (Spain).
* Decision on participation is still pending.
Cooperation with Xjenza Malta
For the JTC2027, EP PerMed is cooperating with the Maltese funding agency Xjenza Malta. Through the Access2Partnerships (A2P) Scheme, Malta-based researchers participating in the EP PerMed Call as partners on own funds may be eligible for up to €300,000 per project to support their involvement in a successfully selected proposal, subject to a successful national application to Xjenza Malta.
Further information on the national application procedure, specific scheme deadlines, eligibility requirements, applicable conditions and submission requirements can be found on Xjenza Malta’sAccess2Partnerships (A2P) Scheme webpage.
Please note: The information provided in this pre-announcement is indicative and may be subject to changes and is not legally binding to funding organisations. Additional funding organisations might join the call before the official publication or leave the funders consortium.
Interested applicants are encouraged to initiate scientific contacts with potential project consortium partners for applications.
The final call information is expected to be published on the EP PerMed website in November 2026.
List of Regional/National Contacts
* Final decision for participation is still pending.